<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04374253</url>
  </required_header>
  <id_info>
    <org_study_id>WN42171</org_study_id>
    <secondary_id>2020-000766-42</secondary_id>
    <nct_id>NCT04374253</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)</brief_title>
  <official_title>An Open-Label, Multicenter, Rollover Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, rollover study to evaluate the safety, tolerability, and
      efficacy of long-term administration of open-label gantenerumab in participants with AD who
      completed Study WN29922 or WN39658, either the double-blind or open-label extension (OLE)
      part.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who were in the active arm in the double blind part and those who have completed
      OLE part in the parent study, will continue receive open-label gantenerumab 510 mg
      sub-cutaneously (SC) every 2 weeks (Q2W). Participants who are naive to gantenerumab
      treatment will be required to undergo the 3 step uptitration scheme as in the parent study
      before receiving target dose of open label gantenerumab.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 29, 2020</start_date>
  <completion_date type="Anticipated">September 21, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From Baseline (OLE Day 1) to Week 104</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Score</measure>
    <time_frame>From Baseline (OLE Day 1) to Week 104</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>From Baseline (OLE Day 1) to Week 104</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Amyloid-Related Imaging Abnormalities-Haemosiderin deposition (ARIA-H) Confirmed by MRI</measure>
    <time_frame>From Baseline (OLE Day 1) to Week 104</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Injection-Site Reactions (ISRs)</measure>
    <time_frame>From Baseline (OLE Day 1) to Week 104</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Dementia Rating (CDR) Score</measure>
    <time_frame>From Baseline (OLE Day 1) to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mini-Mental State Examination (MMSE) Score</measure>
    <time_frame>From Baseline (OLE Day 1) to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alzheimer Disease Assessment Scale-Cognition, Subscale 11 (ADAS-Cog11) Score</measure>
    <time_frame>From Baseline (OLE Day 1) to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alzheimer Disease Assessment Scale-Cognition, Subscale 13 (ADASCog13) Score</measure>
    <time_frame>From Baseline (OLE Day 1) to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Verbal Fluency Task Score</measure>
    <time_frame>From Baseline (OLE Day 1) to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Coding</measure>
    <time_frame>From Baseline (OLE Day 1) to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Activities Questionnaire (FAQ) Score</measure>
    <time_frame>From Baseline (OLE Day 1) to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alzheimer Disease Cooperative Study Group-Activities of Daily Living (ADCS-ADL) Score</measure>
    <time_frame>From Baseline (OLE Day 1) to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Gantenerumab Administered SC</measure>
    <time_frame>From Baseline (OLE Day 1) to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-drug Antibody (ADA) to Gantenerumab</measure>
    <time_frame>From Baseline (OLE Day 1) to Week 104</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2032</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants, who completed the double-blind part and did not enter the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the Week 104 visit of Study WN29922 or WN39658. This will be considered the OLE baseline visit (OLE Day 1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants, who completed the double-blind part and the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the OLE Week 34 visit or the final dose visit in the Study WN29922 or WN39658 OLE.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gantenerumab</intervention_name>
    <description>Group 1 participants who were in the active arm in the double blind part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg sub-cutaneously (SC) every 2 weeks (Q2W). Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme before receiving target dose of open label gantenerumab, 510 mg sub-cutaneously (SC) every 2 weeks (Q2W).</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gantenerumab</intervention_name>
    <description>Group 2 participants who have completed OLE part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg sub-cutaneously (SC) every 2 weeks (Q2W)</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed Study WN29922 or WN39658, either its double-blind part or OLE part, and did
             not discontinue study drug early

          -  The participant should be capable of completing assessments either alone or with the
             help of the caregiver

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use contraception methods with a failure rate of &lt;1% per
             year (bilateral tubal ligation, male sterilization, hormonal contraceptives that
             inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine
             devices) during the treatment period and for at least 16 weeks after the final dose of
             gantenerumab

        Exclusion Criteria:

          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within
             at least 16 weeks after the final dose of study drug

          -  Prematurely discontinued from Study WN29922 or WN39658

          -  Any medical condition that may jeopardize the participant's safety if he or she
             continues to receive study treatment

          -  Received any investigational treatment other than gantenerumab during or since
             completion of Study WN29922 or WN39658, either its double-blind or OLE part

          -  Evidence of disseminated leptomeningeal hemosiderosis

          -  Evidence of intracerebral macrohemorrhage

          -  Use of prohibited medication

          -  Evidence of ARIA-E on the last MRI scan report in Study WN29922 or WN39658, either its
             double-blind or OLE part
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: WN42171 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>Global-Roche-Genentech-Trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Italiano</name>
      <address>
        <city>Caba</city>
        <zip>C1199ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad Maimonides</name>
      <address>
        <city>Caba</city>
        <zip>C1405BCK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Geriatrico Nuestra Señora de las Nieves</name>
      <address>
        <city>Capital Federal</city>
        <zip>C1427</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEN Centro Especializado en Neurociencias</name>
      <address>
        <city>Córdoba</city>
        <zip>5000FJF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Kremer</name>
      <address>
        <city>Córdoba</city>
        <zip>X5004AOA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Neurociencias San Agustín S.A.</name>
      <address>
        <city>La Plata</city>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Scherbovsky; General Department</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Especialidades Medicas LYS</name>
      <address>
        <city>Santiago</city>
        <zip>7560356</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC</name>
      <address>
        <city>Culiacan</city>
        <zip>80020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mexico Centre for Clinical Research</name>
      <address>
        <city>Mexico</city>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr Jose Eleuterio Gonzalez UANL; Depto.de NeurologíaPta.BajaConsulta</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AVIX Investigación Clínica S.C</name>
      <address>
        <city>Monterrey</city>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital IV Alberto Sabogal Sologuren; Unidad de Investigacion</name>
      <address>
        <city>Bellavista</city>
        <zip>Callao 2</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Internacional; Unidad De Investigacion</name>
      <address>
        <city>Lima</city>
        <zip>15001</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Dos de Mayo; Unidad de Investigacion de Neurologia</name>
      <address>
        <city>Lima</city>
        <zip>Lima 01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBHI Siberian Clinical Center of the Federal Medical and Biological Agency</name>
      <address>
        <city>Krasnoyarsk</city>
        <state>Krasnojarsk</state>
        <zip>660037</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University сlinic of headaches</name>
      <address>
        <city>Moscow</city>
        <state>Moskovskaja Oblast</state>
        <zip>121467</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBMEI HPE &quot;Military Medical Academy n.a. S.M. Kirov&quot; of the MoD of the RF</name>
      <address>
        <city>Sankt-peterburg</city>
        <state>Sankt Petersburg</state>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Autonomous Healthcare Institution &quot;Republican Clinical Neurological Center</name>
      <address>
        <city>Kazan</city>
        <zip>420021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State autonomous institution of healthcare Inter-regional clinical and diagnostic center</name>
      <address>
        <city>Kazan</city>
        <zip>420101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clin Hosp n.a. S.P.Botkin</name>
      <address>
        <city>Moscow</city>
        <zip>125101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NSHI &quot;Central Clinical Hospital #2 of JSC &quot;Russian Railways&quot; n.a. N.A. Semashko&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHI City Clinical Hospital #2 named after V.I. Razumovsky; Psychiatric</name>
      <address>
        <city>Sartatov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebbiolo Center for Clinical Trials</name>
      <address>
        <city>Tomsk</city>
        <zip>634009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

